Table 6.
Multivariate analysis
|
Overall survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| |
|
Model 1 |
|
|
Model 2 |
|
|
Model 3 |
|
| HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
|
PSA,ng/ml |
|
|
|
|
|
|
|
|
|
| ≤10ng/ml |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| >10ng/ml |
0.49 |
(0.13-1.83) |
0.3 |
0.45 |
(0.12-1.74) |
0.2 |
0.45 |
(0.12-1.74) |
0.2 |
|
Extra-prostatic extension | |||||||||
| Yes |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| No |
3.34 |
(0.71-15.66) |
0.1 |
3.75 |
(0.79-17.88) |
0.1 |
3.52 |
(0.74-16.77) |
0.1 |
|
Pelvic nodes involved | |||||||||
| N0 |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| N+ |
1.72 |
(0.50-5.88) |
0.4 |
1.45 |
(0.43-4.93) |
0.5 |
1.41 |
(0.41-4.79) |
0.6 |
|
Surgical margins involved | |||||||||
| No |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| Yes |
1.42 |
(0.46-4.38) |
0.5 |
1.36 |
(0.46-3.99) |
0.6 |
1.31 |
(0.44-3.89) |
0.6 |
|
Seminal vesicles involved | |||||||||
| No |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| Yes |
1.41 |
(0.50-3.97) |
0.5 |
1.06 |
(0.37-3.05) |
0.9 |
1.12 |
(0.38-3.20) |
0.8 |
|
Gleason score | |||||||||
| <7 |
1.0 |
|
|
|
|
|
|
|
|
| ≥7 |
2.19 |
(0.56-8.62) |
0.3 |
|
|
|
|
|
|
|
Gleason score | |||||||||
| ≤7 |
|
|
|
1.0 |
|
|
|
|
|
| >7 |
|
|
|
2.75 |
(0.90-8.42) |
0.08 |
|
|
|
|
Gleason score | |||||||||
| <7 |
|
|
|
|
|
|
1.0 |
|
0.2 |
| =7 |
|
|
|
|
|
|
1.49 |
(0.33-6.81) |
0.6 |
| >7 |
|
|
|
|
|
|
3.56 |
(0.78-16.20) |
0.1 |
|
Stromal -Epithelial IRS Score | |||||||||
| =12/≤2 |
1.0 |
|
0.01 |
1.0 |
|
0.01 |
1.0 |
|
0.01 |
| <12/≤2 |
0.13 |
(0.04-0.44) |
0.001 |
0.14 |
(0.04-0.46) |
0.001 |
0.14 |
(0.04-0.45) |
0.001 |
| =12/>2 |
0.19 |
(0.02-1.37) |
0.1 |
0.21 |
(0.03-1.58) |
0.1 |
0.20 |
(0.02-1.53) |
0.1 |
| <12/>2 | 0.12 | (0.01-1.32) | 0.08 | 0.12 | (0.01-1.43) | 0.09 | 0.11 | (0.01-1.37) | 0.09 |
Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA, Prostate-specific antigen;IRS,Immuno-reactive score.